Loading...
•
Mar 31, 2022
Kiniksa Q1 2022 Earnings Report
Reported first quarter 2022 financial results and provided a corporate update.
Key Takeaways
Kiniksa Pharmaceuticals reported ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022.
ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million
Cash reserves expected to fund operations into at least 2024
Company anticipates continued efficient commercial execution and key progress of its clinical-stage pipeline.
Revenue by Segment
Forward Guidance
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million and cash reserves expected to fund operations into at least 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...